Investigational — not approved anywhere
Bemnifosbuvir
What it isAn investigational oral guanosine nucleotide-analog prodrug that inhibits the hepatitis C NS5B RNA polymerase and has antiviral activity against SARS-CoV-2.
Why this oneIt is being developed as a component of short-course, pangenotypic HCV regimens and was studied as an oral COVID-19 antiviral.
What limits itIt remains investigational and not FDA-approved, so its efficacy and safety in a marketed regimen are not yet established.
NO BOXED WARNINGS
Principal riskNo FDA boxed warning (investigational, not FDA-approved).
Classes and tags
Clinical profile
Mechanism of action: Bemnifosbuvir ballicule
